OKUR — OnKure Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1637715 ·
Last close
$4.12
Market Cap
$166.43M
52W High
$5.38
52W Low
$2.62
ADV30
158,418
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -15,615,000 | -15,157,000 | 198,694,000 | 192,106,000 | 14,341,000 |
| Dec 2025 | 0 | — | -14,125,000 | -13,503,000 | 62,117,000 | 59,050,000 | 5,933,000 |
| Sep 2025 | 0 | — | -15,501,000 | -14,699,000 | 72,835,000 | 70,331,000 | 6,407,000 |
| Jun 2025 | 0 | — | -16,324,000 | -15,390,000 | 86,070,000 | 83,374,000 | 7,904,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-51,828,000
Investing CF
$-46,000
Financing CF
$163,000
CapEx
$-46,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.41
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-214,241,000
Inventory
—
Receivables
—
ST Investments
$15,979,000
EBIT TTM
$-60,584,000
Pretax Income TTM
$-59,517,000
Interest Exp TTM
$226,000
Analysts
5
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -62,950,000 | -59,517,000 | 62,117,000 | 5,933,000 | — | -51,828,000 |
| Dec 2024 | 0 | -54,386,000 | -52,673,000 | 114,907,000 | 11,079,000 | — | -51,117,000 |
| Dec 2023 | 0 | -36,934,000 | -35,311,000 | 35,734,000 | 137,576,000 | — | -34,546,000 |
| Dec 2022 | 0 | -29,766,000 | -29,512,000 | 15,999,000 | 70,417,000 | — | -26,953,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.13
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| HRTX | HERON THERAPEUTICS, INC. /DE/ | $167.19M | $0.88 | — |
| SPRO | Spero Therapeutics, Inc. | $165.60M | $2.86 | — |
| PRQR | ProQR Therapeutics N.V. | $165.42M | $1.57 | — |
| ORMP | ORAMED PHARMACEUTICALS INC. | $165.34M | $4.04 | — |
| ENLV | Enlivex Ltd. | $164.88M | $0.68 | — |
News headlines (Yahoo Finance, 1h cache)
OnKure Therapeutics Reports First Quarter 2026 Financial Results
2026-05-05 20:05 · Yahoo
TMO Q1 Earnings Preview: Will Life Sciences Solutions Lead Results?
2026-04-16 13:18 · Yahoo
OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies
2026-03-27 12:00 · Yahoo
OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
2026-03-12 20:05 · Yahoo
Promising Penny Stocks To Watch In December 2025
2025-12-09 18:05 · Yahoo
OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update
2025-11-06 21:03 · Yahoo
OnKure Therapeutics to Participate in Upcoming Investor Conferences
2025-11-04 21:05 · Yahoo
3 Promising Penny Stocks With Market Caps Under $200M
2025-10-31 18:04 · Yahoo
Companies Like OnKure Therapeutics (NASDAQ:OKUR) Could Be Quite Risky
2025-08-19 10:57 · Yahoo
OnKure Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update
2025-08-12 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.